T cell bispecific antibody for the immune-mediated killing of HER2+ breast cancer cells

October 3, 2018, Vall d'Hebron Institute of Oncology
The engineered bispecific antibody targets p95HER2 (blue fragment), which is unique to malignant breast cancer cells (brown). The antibody can therefore guide T cells (blue cells) to cancer cells without attacking healthy breast epithelial cells (pink). Credit: Vall d’Hebron Institute of Oncology (VHIO)

Not so long ago, immunotherapy against cancer was positioned as an emerging or even promising treatment, but not one with a proven track record. Today however, novel immunotherapeutics across different tumor types, either as mono therapy or in combination, are increasingly becoming one of the most innovative and powerful anti-cancer strategies.

One of the major challenges in ensuring that these novel treatments realize their true potential has been successfully equipping the immune system to launch its attack exclusively on tumour excluding all healthy tissues. Up until now.

Research led by Joaquín Arribas, Director of Preclinical Research at the Vall d'Hebron Institute of Oncology (VHIO), ICREA Professor, and Scientific Director of the Center for the Biomedical Research Network in Oncology (CIBERONC), has turned this obstacle into a therapeutic opportunity.

Published in Science Translational Medicine, the study, first co-authored by Irene Rius-Ruiz, Graduate Student of VHIO's Growth Factors Group, reveals that p95HER2-T cell bispecific antibody (TCB) can successfully guide immune cells, known as lymphocytes, directly to for their targeted killing.

This direct delivery is achieved thanks to the p95HER2 protein, which is only located in tumor cells. Representing a new therapeutic avenue and fresh hope for patients who have ceased to respond to current therapies, this novel immune-based approach can be used to tackle certain HER2+ breast cancers through its exclusive targeting of cancerous cells.

p95HER2-TCB: guiding the immune system for the targeted killing of HER2-positive breast cancer cells

T cell bispecific antibodies constitute a promising approach in harnessing the immune system to mount its anti-cancer response, and represent an increasingly valuable addition to the current arsenal against cancer. Not only are they highly specific but they can also hone in on one protein among tens of thousands, in this particular case, p95HER2.

A Q&A Round with Joaquín Arribas, Director of Preclinical Research at VHIO and Irene Rius Ruiz, Graduate Student of VHIO's Growth Factors Group. Credit: Vall d'Hebron Institute of Oncology (VHIO)

Furthermore, each antibody molecule has a bipartite structure containing two protein-binding sites. This means that they can simultaneously attach to and cancerous ones as well as take the lymphocytes hand-in-hand directly to the for their subsequent destruction.

Acting as a magnet that lures the patient's immune system solely to tumor cells, p95HER2-TCB enables a targeted response by attacking these cells directly without affecting normal cells. "The immune system has the natural capacity to fight against disseminated disease. To do so more effectively, it must be better equipped to recognize and act against malignant cells. While bispecific antibodies are designed to do just that, they often signpost T cells to healthy ones," explains Joaquín Arribas, corresponding author of the study.

He continues, "Thanks to the distinct specificity of p95HER2-TCB and p95HER2's exclusive location in , we have achieved a 'home delivery' of immune-based therapy. Our findings represent an important step towards ensuring that the immune system can successfully deliver its powerful anti-cancer blows."

Immunotherapies for cancer are proving increasingly more effective in the treatment of metastatic disease. Generally, advanced and metastatic cancers eventually develop resistance to different lines of therapies. When patients eventually cease to respond to current therapies, leading to cancer cell spread, they have few therapeutic options available.

While the immune system represents powerful weaponry in thwarting the spread of disease, it can only effectively do so by recognizing and launching its attack on malignant cells. "The real added value of our findings is that the bispecific antibody, p95HER2-TCB, directs lymphocytes exclusively to tumour cells harboring p95HER2," observes Irene Rius Ruiz, first author of the study.

Approximately 10% of patients with HER2-positive breast cancers expressing p95HER2 could stand to benefit from this novel strategy.

"While our approach can only be extended to a relatively small subset of patients with HER2-positive disease, for those who stand to gain, the benefits could be significant. By more precisely matching novel therapy to a particular patient population, we are getting closer to delivering on the true promise of precision medicine in oncology," says Irene Rius Ruiz.

Treatment with the T cell bispecific antibody (TCB) for the p95HER2 fragment reduced tumor growth (colored sections) in mouse models of HER2-positive breast cancer. Credit: I. Rius Ruiz et al., Science Translational Medicine (2018)

These findings are the fruit of a decade of research at VHIO, beginning with Joaquín Arribas' group's identification of the p95HER2 protein, which was initially used as a biomarker to identify a subgroup of patients with HER2-positive breast cancer who no longer responded to standard therapies.

Their later discovery that this protein only resides on the surface of as opposed to healthy cells led to the development of a specific targeted therapy.

As a leading reference in advancing modelling systems, VHIO is dedicated to delivering the predictive data required to reliably inform the clinical development of innovative agents and evidence reproducibility before moving to the clinic.

VHIO's Growth Factors Group focuses on more accurately modeling anti-tumor immunotherapy strategies and has generated humanized patient-derived xenograft models (Hu PDXs), in which the human immune system is established in immunodeficient mice. These experimental models have been invaluable in validating the efficacy of the p95HER2-T cell bispecific antibody.

Having now completed the pre-clinical phase of development, Arribas' team will seek to advance the so that it can be administered in humans for investigation in clinical trials. Next steps will also include developing additional therapies against p95HER2 such as antibody-drug conjugates or chimeric antigen receptors (CARs).

"These future treatments will likely be as effective and safe as p95HER2-TCB. We are confident that our findings will enable the exclusive targeting of malignant cells by different means through p95HER2," concludes Joaquín Arribas.

Reflective of VHIO's purely multidisciplinary and translational research model, several of its preclinical, translational and clinical groups, along with colleagues belonging to CIBERONC, have collaborated in this research.

The project has also relied on the participation of other physician-scientists and oncology professionals of the Vall d´Hebron University Hospital and within the Vall d´Hebron Barcelona Hospital Campus.

Explore further: New cancer vaccine shows early promise for patients with HER2-positive cancers

More information: I. Rius Ruiz el al., "p95HER2–T cell bispecific antibody for breast cancer treatment," Science Translational Medicine (2018). stm.sciencemag.org/lookup/doi/ … scitranslmed.aat1445

Related Stories

New cancer vaccine shows early promise for patients with HER2-positive cancers

September 30, 2018
Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic, according ...

Two-pronged antibodies draw immune killers directly to cancer cells

May 30, 2018
Our immune system's arsenal of defenses usually protects us from cancer. But sometimes, cancer cells overwhelm or evade this elaborate defense system.

Researchers discover new approach to stimulate an immune response against tumor cells

January 30, 2018
New drugs that activate the immune system to target cancer cells have improved the lives of many patients with cancer. However, immunotherapies are not effective in all patients, and the success of these therapies depends ...

New cancer immunotherapy shows promise in early tests

July 2, 2018
Much cancer immunotherapy research has focused on harnessing the immune system's T cells to fight tumors, "but we knew that other types of immune cells could be important in fighting cancer too," says Ashish Kulkarni at the ...

Breast cancer: Discovery of a protein linked to metastasis

May 7, 2018
Jean-François Côté, a researcher at the Montreal Clinical Research Institute (IRCM) and professor at Université de Montréal's Faculty of Medicine, studies metastasis, the leading cause of cancer-related death. Recently, ...

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Recommended for you

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Major breakthrough in quest for cancer vaccine

December 6, 2018
The idea of a cancer vaccine is something researchers have been working on for over 50 years, but until recently they were never able to prove exactly how such a vaccine would work.

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Scientists develop new technology for profiling unique genetic makeup of myeloma tumor cells

December 6, 2018
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells—outlining how cancer cells hijack specific pathways for uncontrolled proliferation—will lead to more efficient ways to fight it. Joint ...

Putting the brakes on tumor stealth

December 6, 2018
New research undertaken at Monash University has shed new light on how some cancers are able to escape our immune system.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.